,dupilumab

Sunyoung Shim1,2, Jung Sun Kim1, Jeong Yee3

  • 1College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea.

PubMed
概括

高龄,结膜炎病史和较高的湿疹区域和严重性指数 (EASI) 评分是阿托皮性皮肤炎 (AD) 患者中与dupilumab相关的眼睛表面疾病 (DAOSD) 的关键风险因素. 一个新的评分系统有助于预测DAOSD风险,以更好地管理患者.